New therapeutic approaches, which are under preclinical evaluation, include the use of antibodies that neutralize IL-33 or ST2, especially in tumours with intensive accumulation of Treg cells or fibrous stroma [96,108,113]. Here, IL1RL1 is linked to neoplasm.